Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer

Prostate

Volumn 63, Issue 1, 2005, Pages 56-64

  Yamanaka, Hidetoshi ^a   Ito, Kazuto ^b   Naito, Seiji ^c   Tsukamoto, Taiji ^d   Usami, Michiyuki ^e   Fujimoto, Hiroyuki ^f   Matsuoka, Naoki ^f   Fukui, Iwao ^g   Harada, Masaoki ^h   Ohashi, Yasuo ⁱ   Kotake, Toshihiko ^j   Kakizoe, Tadao ^f  

^a Kurosawa Hospital   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

^h KANAGAWA CANCER CENTER   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j Kotake Clinic   (Japan)

more..

Author keywords

External beam radiation therapy; Intermittent hormonal therapy; Prostate cancer

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; INTERMITTENT HORMONAL THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CHLORMADINONE ACETATE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 20144362098     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20171     Document Type: Article

References (23)

1. Tominaga Y, Aoki K, Hanai A, Kurihara N. editors. Cancer statistics-incidence, mortality, survival. Tokyo: Shinohara Shuppan Co., Ltd. 1993.
2. Kuroishi T. Research on the validity of mass screening for prostate cancer. (Principal investigator; Watanabe H.), supported by grant from The Ministry of Health and Welfare, report in 1994 and 1995.
3. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
4. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Grignon D, Caplan R, Cox JD. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the radiation therapy oncology group. Urology 1995;45:616-623.
5. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50:1243-1252.
6. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-2790.
7. Yamamoto T, Ito K, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H. Long-term follow-up of prostate cancer with clinical T3N0M0 disease treated by LH-RH agonist monotherapy. Jpn J Urol 2000;91:188.
8. Goldenberg SL, Bruchovsky N, Cleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995;45:839-845.
9. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 1996;48:800-804.
10. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience. Urology 1998;51:137-144.
11. Buhler KR, Santucci RA, Royai RA, Whitney SC, Vessella RL, Lange PH, Ellis WJ. Intermittent androgen supression in the LNCaP prostate cancer xenograft model. Prostate 2000;43:63-70.
12. Horwich A, Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P, Dearnaley DP. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998;81: 96-99.
13. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-2550.
14. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35:27-31.
15. Rambeaud JJ. Intermittent complete androgen blockade in metastatic prostate cancer. Eur Urol 1999;35:32-36.
16. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43:233-240.
17. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001;58:240-245.
18. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, Brabbins DS, Hollander J, Chen PY, Martinez AA. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996;36:565-571.
19. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995;32:287-292.
20. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-1380.
21. Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: Radiation therapy or surgery? Int J Radiat Oncol Biol Phys 1997;38:723-729.
22. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154(1):131-138.
23. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501-510.